Cover Image

Granulomatous variant of scleromyxedema successfully treated with topical ruxolitinib, dapsone and intravenous immunoglobulin

Saved in:

Bibliographic Details
Main Authors:	Donglin Zhang, BA (Author), Kimberly Sable, MD (Author), Allison Miller, MD (Author), Molly Hinshaw, MD (Author), Timothy Schmidt, MD (Author), Bridget E. Shields, MD (Author)
Format:	Book
Published:	Elsevier, 2023-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

An unusual case of granulomatous scleromyxedema
by: Lauren Michelle, BA, et al.
Published: (2022)

Delayed granulomatous eruption of the nose associated with ruxolitinib
by: Margaret Brown, MD, et al.
Published: (2020)

Scleromyxedema with Subcutaneous Nodules: Successful Treatment with Thalidomide and Intravenous Immunoglobulin
by: M. Dolenc-Voljč, et al.
Published: (2013)

Treatment of granulomatous perioral dermatitis with 1.5% topical ruxolitinib cream
by: Sophia S. Tran, BS, et al.
Published: (2024)

Coexistence of scleromyxedema and Sneddon syndrome
by: Antonio Furci, MD, et al.
Published: (2021)

Treatment of a Complex Case of Scleromyxedema Using a Novel Intravenous Immunoglobulin Preparation
by: Anastasia Sophie Vollmer, et al.
Published: (2024)

Combination intravenous immunoglobulin, oral prednisone, and methotrexate for managing scleromyxedema: case report and literature discussion
by: Gaia Fasano, et al.
Published: (2023)

Paraneoplastic atypical scleromyxedema with advanced gastric cancer
by: Se Jin Oh, MD, et al.
Published: (2017)

Pemphigoid gestationis and intravenous immunoglobulin therapy
by: Anes Yang, MD, BMed, MPH, et al.
Published: (2018)

Topical ruxolitinib in the treatment of refractory facial seborrheic dermatitis
by: Eleanor Pope, BA, et al.
Published: (2022)

A case of nivolumab-induced scleroderma-like syndrome successfully treated with intravenous immunoglobulin
by: Alexa DeMaio, MD, et al.
Published: (2023)

Efficacy of topical ruxolitinib for cutaneous dermatomyositis
by: Aviya Lanis, MD, et al.
Published: (2024)

Pregnancy associated anti-TIF1 dermatomyositis responsive to intravenous immunoglobulin
by: Jason Kieffer, MD, et al.
Published: (2024)

Topical ruxolitinib for the treatment of granuloma faciale
by: Alan Wong, DO, et al.
Published: (2023)

Ruxolitinib cream for the treatment of granuloma annulare
by: Austin J. Piontkowski, BS, et al.
Published: (2024)

Recalcitrant, delayed pressure urticaria treated with long-term intravenous immunoglobulin
by: Yssra S. Soliman, MD, et al.
Published: (2020)

Intravenous immunoglobulin-induced eczematous dermatitis treated with dupilumab
by: Katelyn Singh, MD, et al.
Published: (2024)

White Blood Cell and Neutrophil Counts and Response to Intravenous Immunoglobulin in Kawasaki Disease
by: Taichiro Muto MD, PhD, et al.
Published: (2019)

Response to low-dose intravenous immunoglobulin in a case of recalcitrant Darier disease
by: Adeline Legrand, MD, et al.
Published: (2020)

Optimizing the speed of intravenous immunoglobulin infusion for Kawasaki Disease
by: Chia-Yi Chin, MD, MS
Published: (2024)

Cystic Neutrophilic Granulomatous Mastitis Treatment with Consecutive Dapsone and Adalimumab
by: Samir Kamat, et al.
Published: (2022)

Intravenous immunoglobulin-refractory necrobiotic xanthogranuloma successfully treated with tofacitinib 2% cream
by: Neda Shahriari, MD, et al.
Published: (2023)

Topical steroid withdrawal treated with ruxolitinib cream
by: Moira Shea, BS, et al.
Published: (2024)

Ruxolitinib cream for the treatment of cutaneous sarcoidosis
by: Jeffrey S. Smith, MD, PhD, et al.
Published: (2023)

Macroglossia and lip edema: A case of paraproteinemia-associated scleredema responsive to intravenous immunoglobulins
by: Onjona B. Hossain, BS, et al.
Published: (2024)

Recalcitrant Hailey-Hailey disease successfully treated with topical ruxolitinib cream and dupilumab
by: Juna Khang, BA, et al.
Published: (2023)

Puffy hand syndrome with histopathological evidence of a cutaneous granulomatous reaction to starch in the setting of prior intravenous drug use
by: Tatiana M. Barrera, BA, et al.
Published: (2023)

Severe dapsone-induced hypoalbuminemia in a case of mucous membrane pemphigoid
by: Jasmine Flament, MD, et al.
Published: (2020)

Development of sebaceous carcinoma in a patient on ruxolitinib therapy
by: Noreen Mohsin, BS, et al.
Published: (2022)

Development of cyclosporine-induced linear IgA bullous dermatosis despite concurrent use of dapsone
by: Karissa Libson, BA, et al.
Published: (2023)

Successful treatment of alopecia totalis with ruxolitinib in a preadolescent patient
by: Danielle M. Peterson, MD, et al.
Published: (2020)

Treatment of cutaneous lupus with topical ruxolitinib cream
by: Jonathan J. Park, PhD, et al.
Published: (2022)

SARS-CoV-2: A potential trigger of dermato-neuro syndrome in a patient with scleromyxedema
by: Mike Fritz, BS, et al.
Published: (2021)

Recalcitrant lichen planus pigmentosus treated with topical ruxolitinib
by: Hannah L. Cornman, BS, et al.
Published: (2023)

The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: A case report
by: Deesha Desai, BS, et al.
Published: (2024)

Improvement of plaquelike cutaneous mucinosis after intravenous immunoglobulins treatment
by: Jorge Magdaleno-Tapial, MD, et al.
Published: (2020)

Dapsone-responsive inflammatory dermatitis with features of subcorneal pustular dermatosis and bullous pemphigoid
by: Shilpa Ghatnekar, MS, et al.
Published: (2022)

Idiopathic hypereosinophilic syndrome with eosinophilic cellulitis-like cutaneous involvement treated with mepolizumab and dapsone
by: Madeleine Lachance, MD, et al.
Published: (2022)

Letter in response to the case report "Topical ruxolitinib in the treatment of refractory facial seborrheic dermatitis"
by: Meron Teklu, MD, et al.
Published: (2023)

Dapsone: a steroid-sparing drug for refractory immunoglobulin A vasculitis?
by: Jin-Soon Suh
Published: (2020)